BIOV Share Price Performance
CHF 28.40
-7.60 (-21.11%)
Price CHF 28.40
Share PriceCHF 28.40
Is BioVersys (VTX:BIOV) A Risky Investment?
Sep 27
BioVersys AG Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
BIOV Community Narratives
There are no narratives available yet.
BioVersys AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.31
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,478.84%
- Debt/Equity Ratio
- 25.8%
BioVersys AG Competitors
Snowflake Analysis
About BIOV
- Founded
- 2008
- Employees
- 29
- CEO
- WebsiteView website
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop novel ansamycin leads from BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swiss Market Performance
- 7 Days: 3.1%
- 3 Months: 3.2%
- 1 Year: 3.4%
- Year to Date: 6.2%
The market is up 3.1% over the last week, with the Healthcare sector leading the way, up 6.7%. In the last year, the market has climbed 3.4%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›